Tagrisso (Osimertinib) is prescribed by oncologists for the following indications: 🔹 Adjuvant Therapy: After radical surgery in patients with NSCLC harboring EGFR mutations (exon 19 deletion or L858R substitution). 🔹 First-Line Therapy: Treatment of patients with locally advanced or metastatic NSCLC with EGFR mutations. 🔹 Second-Line Therapy: Treatment of metastatic NSCLC with a positive T790M mutation after progression on therapy with other EGFR inhibitors.

Dosage and administration

Sales Form: 1 pack contains 30 tablets of 80 mg.⚠️ INSTRUCTIONS FOR USE: Dosage Regimen: The standard dosage is 80 mg (1 tablet) once daily. Method: The tablet should be swallowed whole with water. It can be taken with or without food at the same time each day. Special Features: If the patient has difficulty swallowing the tablet whole, it can be dispersed in 50 ml of non-carbonated water (no other liquids should be used), stirred thoroughly, and consumed immediately. Duration: Treatment continues until disease progression or the occurrence of severe side effects. Storage: Store in the original packaging at temperatures up to 30°C.

⛔ Hypersensitivity: Hypersensitivity to osimertinib. ⛔ Pregnancy and Family Planning: The drug is contraindicated in pregnant women due to risk to the fetus. Women must use reliable contraception during therapy and for 2 months after; men should use it for 4 months. ⛔ Lactation: Breastfeeding is prohibited during the treatment period. ⛔ Interactions: Concomitant use with St. John's wort preparations is strictly not recommended. ⛔ Pediatric Use: Safety for patients under 18 years of age has not been established.

Tagrisso is generally well-tolerated; however, the following side effects may occur: 🧪 Skin Reactions: Dry skin, rash, itching, inflammation around the nails (paronychia). 🤢 GI Tract: Diarrhea (most common), stomatitis (mouth sores), decreased appetite. 🩸 Blood: Decreased levels of white blood cells, platelets, or red blood cells. 🫁 Lungs: In rare cases — interstitial lung disease (ILD). If sudden cough or shortness of breath appears, seek medical attention immediately. ❤️ Heart: QT interval prolongation (ECG monitoring required for patients at risk). ⚠️ Important: If signs of heart failure or acute lung inflammation appear, therapy should be suspended.

Tagrisso 80 — Osimertinib 80 mg, 30 pcs, AstraZeneca

100% original product

Active ingredient

Osimertinib

Manufacturer

AstraZeneca

Dosage 80 mg

Dosage form Tablets

Tablets per pack 30

Tagrisso 80 — Osimertinib 80 mg (30 Tablets)

Name: Tagrisso 80
Brand: AstraZeneca
SKU: PROD-283
Price: 114733 UAH
Availability: InStock

114733₴ ~~123515₴~~ -7% On order · from 7 days

Tagrisso (Osimertinib) is an advanced antineoplastic medication belonging to the third generation of targeted epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. It is specifically designed to treat non-small cell lung cancer (NSCLC) harboring specific genetic mutations. The uniqueness of osimertinib lies in its ability to effectively target the tumor even in the presence of the T790M mutation, which often causes resistance to previous generations of drugs.

Manufacturer: AstraZeneca. Tagrisso has the ability to cross the blood-brain barrier, making it highly effective in treating brain metastases. The drug significantly increases progression-free survival while maintaining a high quality of life for patients.

Key Features:

✅ Third-Generation TKI: Overcomes resistance to first- and second-generation therapies (T790M mutation).
✅ CNS Metastasis Control: High activity against brain lesions.
✅ Targeted Precision: Selectively blocks cancer cell signaling pathways without affecting wild-type healthy cells.

Tagrisso (Osimertinib) is prescribed by oncologists for the following indications:

🔹 Adjuvant Therapy: After radical surgery in patients with NSCLC harboring EGFR mutations (exon 19 deletion or L858R substitution).
🔹 First-Line Therapy: Treatment of patients with locally advanced or metastatic NSCLC with EGFR mutations.
🔹 Second-Line Therapy: Treatment of metastatic NSCLC with a positive T790M mutation after progression on therapy with other EGFR inhibitors.

Sales Form: 1 pack contains 30 tablets of 80 mg.

⚠️ INSTRUCTIONS FOR USE:

Dosage Regimen: The standard dosage is 80 mg (1 tablet) once daily.
Method: The tablet should be swallowed whole with water. It can be taken with or without food at the same time each day.
Special Features: If the patient has difficulty swallowing the tablet whole, it can be dispersed in 50 ml of non-carbonated water (no other liquids should be used), stirred thoroughly, and consumed immediately.
Duration: Treatment continues until disease progression or the occurrence of severe side effects.
Storage: Store in the original packaging at temperatures up to 30°C.

⛔ Hypersensitivity: Hypersensitivity to osimertinib.
⛔ Pregnancy and Family Planning: The drug is contraindicated in pregnant women due to risk to the fetus. Women must use reliable contraception during therapy and for 2 months after; men should use it for 4 months.
⛔ Lactation: Breastfeeding is prohibited during the treatment period.
⛔ Interactions: Concomitant use with St. John's wort preparations is strictly not recommended.
⛔ Pediatric Use: Safety for patients under 18 years of age has not been established.

Tagrisso is generally well-tolerated; however, the following side effects may occur:

🧪 Skin Reactions: Dry skin, rash, itching, inflammation around the nails (paronychia).
🤢 GI Tract: Diarrhea (most common), stomatitis (mouth sores), decreased appetite.
🩸 Blood: Decreased levels of white blood cells, platelets, or red blood cells.
🫁 Lungs: In rare cases — interstitial lung disease (ILD). If sudden cough or shortness of breath appears, seek medical attention immediately.
❤️ Heart: QT interval prolongation (ECG monitoring required for patients at risk).
⚠️ Important: If signs of heart failure or acute lung inflammation appear, therapy should be suspended.